1. Home
  2. LAES vs GLUE Comparison

LAES vs GLUE Comparison

Compare LAES & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SEALSQ Corp

LAES

SEALSQ Corp

HOLD

Current Price

$4.43

Market Cap

366.0M

Sector

Technology

ML Signal

HOLD

Logo Monte Rosa Therapeutics Inc.

GLUE

Monte Rosa Therapeutics Inc.

HOLD

Current Price

$16.23

Market Cap

308.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LAES
GLUE
Founded
2022
2019
Country
Switzerland
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
366.0M
308.8M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
LAES
GLUE
Price
$4.43
$16.23
Analyst Decision
Strong Buy
Buy
Analyst Count
1
2
Target Price
$6.00
$15.00
AVG Volume (30 Days)
19.9M
980.7K
Earning Date
12-11-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.25
Revenue
$10,978,000.00
$181,538,000.00
Revenue This Year
N/A
$66.94
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$64.10
Revenue Growth
N/A
1112.27
52 Week Low
$0.35
$3.50
52 Week High
$11.00
$16.66

Technical Indicators

Market Signals
Indicator
LAES
GLUE
Relative Strength Index (RSI) 44.61 72.97
Support Level $3.30 $13.27
Resistance Level $4.47 $16.66
Average True Range (ATR) 0.49 1.02
MACD -0.10 0.08
Stochastic Oscillator 37.34 88.50

Price Performance

Historical Comparison
LAES
GLUE

About LAES SEALSQ Corp

SEALSQ Corp develops certified secure microcontrollers and implements post-quantum cryptography. The company develops solutions including post-quantum microchips and devices that can be used in a variety of applications, from multi-factor authentication, home automation, and IT network infrastructure to automotive, industrial automation, and control systems. The company's vaultIC range offers a set of ready-to-use secure elements designed to implement embedded security for any kind of device with fast time-to-market and high flexibility. The company's products include VaultIC155, VaultIV18x, VaultIC292, and VaultIC40x. The company generates a majority of its revenue from North America.

About GLUE Monte Rosa Therapeutics Inc.

Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.

Share on Social Networks: